title: Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
abstract: OBJECTIVE
  To prospectively assess the feasibility and efficacy of a hypofractionated accelerated radiotherapy regimen (72 Gy in 24 daily fractions, 3 Gy per fraction) in patients (pts) with non-resectable non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  We included 25 pts with a histologically or cytologically proven NSCLC, with KPS > or = 70 and < or =10% weight loss over prior three months, and with tumour stage I/II medically inoperable (9 pts) or non-resectable stage III a/b without pleural effusion (16 pts). Eleven pts received induction chemotherapy. No more than 30% of the combined lung volume could receive more than 25 Gy and the maximal biological effective dose to the spinal cord was maintained below 44 Gy.
  
  
  RESULTS
  No grade-4 acute toxicity event was reported. Two pts had a treatment break because of grade-3 acute oesophagitis. Twenty-two pts were evaluable for long-term toxicity (median follow-up=9.7 months, range 4 to 30.2 months). There were 4 Grade-1 pulmonary and 2 Grade-1 oesophageal long-term toxicity events. Twenty-two pts were evaluable for tumour response with 7 complete and 8 partial responses, 5 stable diseases and 2 progressive diseases. The actuarial 1-year overall and thoracic-progression-free survival rates were 68% and 72% respectively.
  
  
  CONCLUSIONS
  This study demonstrates the feasibility of the experimental radiotherapy schedule, however more data are needed to confirm its efficacy.
authors.affiliation: Department of Radiation Oncology, St Luke's Hospital, Highfield Road, Dublin 4, Ireland.
authors.forename: Pierre
authors.initials: P
authors.lastname: Thirion
authors.forename: Ola
authors.initials: O
authors.lastname: Holmberg
authors.forename: Conor D
authors.initials: CD
authors.lastname: Collins
authors.forename: Carmel
authors.initials: C
authors.lastname: O'Shea
authors.forename: Michael
authors.initials: M
authors.lastname: Moriarty
authors.forename: Maeve
authors.initials: M
authors.lastname: Pomeroy
authors.forename: Catriona
authors.initials: C
authors.lastname: O'Sullivan
authors.forename: Steve
authors.initials: S
authors.lastname: Buckney
authors.forename: John
authors.initials: J
authors.lastname: Armstrong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000517:prevention & control*; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects* / Q000379:methods*; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome